眼科領域的合作與許可協議（2019-2026）

眼科領域併購的權威基準

我們在眼科領域的合作涵蓋了廣泛的領域，包括慢性疾病和威脅視力的疾病，我們的合作結構體現了專門的管理方法、標靶治療和獨特的臨床開發途徑。

本報告對 374 項眼科合作及許可協議進行了全面系統的分析，清晰且基於證據地闡述了整個市場夥伴關係的設計、談判和執行方式。

充分了解市場標準。

本報告將幫助您全面了解眼科領域的交易結構，並使您能夠：

• 自信地對標類似交易
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解交易條款如何根據開發階段、資產類型和合作夥伴情況而有​​所不同。
• 支持實證評估和結構性決策
• 我們將根據實際交易數據進行內部討論，而不是根據假設。
• 了解主要企業如何處理交易
• 在高度專業化、創新主導的治療領域中，可視化合作夥伴行為和重複交易結構。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，使您能夠詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度在眼科夥伴關係中至關重要，尤其是在需要特殊管理方法和長期治療方法的領域，以便了解價值、風險和控制是如何分配的。
• 它旨在為實際的業務發展和策略制定提供幫助。

本報告廣泛用於以下用途：

• 建置和基準測試實際交易
• 在清晰的市場環境下準備談判
• 合作機會及交易對象評估
• 支援穩健且引人注目的數據驅動型內部策略
• 本報告內容
• 眼科領域共有 374 項合作與許可協議
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 可全文搜尋的合約目錄（依公司、治療領域及技術分類）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 交易趨勢分析、關鍵交易和活躍負責人
• 關於眼科領域交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易覆蓋範圍和合約層面的洞察，為如何在眼科領域建立、談判和評估夥伴關係提供可靠的、基於證據的指導。

目錄

摘要整理

第1章：引言

第2章：眼科醫療領域併購趨勢

• 介紹
• 在眼科領域合作多年。
• 眼科領域的合夥（依交易類型分類）
• 眼科領域的合作關係（按行業分類）
• 眼科領域的合作（依發展階段分類）
• 眼科領域的合作（依技術類型分類）
• 眼科領域的合作（依治療適應症分類）

第3章 眼科領域合夥企業的財務條件

• 介紹
• 雙方將在眼科領域公開合作的財務條款。
• 眼科領域夥伴關係的關鍵價值
• 眼科相關服務需預付費。
• 眼科相關合約的里程碑付款
• 眼科藥物的特許權使用費率

第4章：眼科領域的主要交易和相關人員

• 介紹
• 該公司在眼科領域積極尋求合作夥伴關係
• 眼科領域業務最活躍的公司名單
• 眼科產品超值優惠（依價格排序）

第5章：眼科合約文件清單

• 介紹
• 眼科相關合作協議（如有合約）

第6章：眼科醫學交易依治療標靶分類

• 介紹
• 按眼科治療目標分類的交易
• 特價優惠列表
• 交易目錄 - 眼科相關交易（依公司分類）(AZ)
• 交易目錄 - 眼科相關交易（依技術類型分類）
• 交易類型的定義
• 關於這家研究公司
• Current Partnering
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for ophthalmics dealmaking

Ophthalmics partnering spans a range of chronic and vision-threatening conditions, with deal structures reflecting specialised delivery methods, targeted therapies, and distinct clinical development pathways.

This report provides a comprehensive and structured analysis of 374 ophthalmics collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how ophthalmics deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a specialised and innovation-driven therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within ophthalmics partnerships, particularly in areas requiring specialised delivery and long-term treatment approaches.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 374 ophthalmics collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for ophthalmics dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how ophthalmics partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in ophthalmics dealmaking

• 2.1. Introduction
• 2.2. Ophthalmics partnering over the years
• 2.3. Ophthalmics partnering by deal type
• 2.4. Ophthalmics partnering by industry sector
• 2.5. Ophthalmics partnering by stage of development
• 2.6. Ophthalmics partnering by technology type
• 2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 - Financial deal terms for ophthalmics partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for ophthalmics partnering
• 3.3. Ophthalmics partnering headline values
• 3.4. Ophthalmics deal upfront payments
• 3.5. Ophthalmics deal milestone payments
• 3.6. Ophthalmics royalty rates

Chapter 4 - Leading ophthalmics deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in ophthalmics partnering
• 4.3. List of most active dealmakers in ophthalmics
• 4.4. Top ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory

• 5.1. Introduction
• 5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by ophthalmics therapeutic target
• Deal directory
• Deal directory - Ophthalmics deals by company A-Z
• Deal directory - Ophthalmics deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Ophthalmics partnering since 2019
• Figure 2: Ophthalmics partnering by deal type since 2019
• Figure 3: Ophthalmics partnering by industry sector since 2019
• Figure 4: Ophthalmics partnering by stage of development since 2019
• Figure 5: Ophthalmics partnering by technology type since 2019
• Figure 6: Ophthalmics partnering by indication since 2019
• Figure 7: Ophthalmics deals with a headline value
• Figure 8: Ophthalmics deals with upfront payment values
• Figure 9: Ophthalmics deals with milestone payment
• Figure 10: Ophthalmics deals with royalty rates
• Figure 11: Active ophthalmics dealmaking activity since 2019
• Figure 12: Top ophthalmics deals by value since 2019